Table 4.
Pathways with the largest significant difference in KEGG analysis
| Pathway | Count | P value | Corrected P value | Gene |
|---|---|---|---|---|
| Cytokine-cytokine receptor interaction | 52 | 1.14E−27 | 2.92E−25 | IL15RA, IL6, IL11, CCR7, TNFRSF9, IL15, KIT, CXCL10, INHBA, TNFRSF21, CSF3, CCL8, IL26, IL23A, CXCL12, IL11RA, CXCL3, TNFRSF8, CCL20, CCL2, PF4V1, LIF, TNFSF10, IL1R2, CCL3, BMP2, IL20RB, IL1B, IL1A, IL1R1, CXCL8, IL7R, RELT, CXCL1, VEGFA, GDF5, IFNGR1, IL18RAP, CSF2, CXCL6, TNFSF11, IL18R1, TNFRSF1B, CXCL5, CCL7, TGFBR1, PRL, IL24, CXCL2, CCL5, CXCL11, OSMR |
| TNF signalling pathway | 29 | 5.46E−19 | 7.02E−17 | IL6, ICAM1, LIF, CXCL10, MMP3, BIRC3, TNFAIP3, CXCL3, CXCL2, CCL20, IL15, CEBPB, CCL2, NOD2, IL1B, NFKBIA, CXCL1, MAP3K8, JAG1, CSF2, EDN1, IL18R1, TNFRSF1B, CXCL5, MAP3K5, CCL5, PTGS2, SOCS3, MAP3K14 |
| Systemic lupus erythaematosus | 30 | 9.58E−18 | 8.21E−16 | HIST1H3B, HIST1H4A, HIST1H2AH, HIST1H4I, HIST1H3C, HIST1H3J, HIST1H3G, HIST1H2AK, HIST1H2AJ, HIST1H2AL, HIST1H2AG, HIST3H2BB, FCGR3A, HIST1H4L, HIST2H2BF, HIST1H2BE, HIST1H2BN, HIST1H2BL, HIST1H2BM, C3, HIST1H2AI, HIST2H3D, C8A, C1S, HIST2H3A, HIST1H2BJ, HIST2H3C, HIST1H2AE, HIST1H2AD, HIST1H2BB |
| Transcriptional misregulation in cancer | 29 | 4.51E−14 | 2.90E−12 | IL6, HIST1H3B, CCR7, BCL2A1, NFKBIZ, HIST1H3J, NR4A3, HIST1H3G, CD14, BIRC3, HIST2H3D, CDKN2C, IGF1, CEBPB, HIST1H3C, IL1R2, PLAU, GRIA3, CXCL8, ID2, HIST2H3A, CSF2, MEF2C, ETV1, MMP3, HIST2H3C, SPINT1, MEIS1, FOXO1 |
| Alcoholism | 28 | 2.35E−13 | 1.21E−11 | HIST1H3B, HIST1H4A, HIST1H4I, HIST1H3C, HIST1H3J, HIST1H3G, HIST2H3A, HIST1H2AK, HIST1H2AJ, HIST1H2AL, MAOA, HIST1H2AG, HIST3H2BB, HIST2H2BF, HIST1H2BE, HIST1H2BN, HIST1H2BL, HIST1H2BM, HIST1H2AI, HIST2H3D, HIST1H2AH, HIST1H4L, SLC29A1, HIST1H2BJ, HIST2H3C, HIST1H2AE, HIST1H2AD, HIST1H2BB |
| Rheumatoid arthritis | 21 | 3.59E−13 | 1.54E−11 | IL6, IL1B, IL1A, CXCL12, CSF2, CXCL6, CCL20, IL11, IL15, CXCL8, CXCL5, CCL2, TLR2, CXCL1, ICAM1, MMP3, CCL5, VEGFA, IL23A, TNFSF11, CCL3 |
| Chemokine signalling pathway | 26 | 1.79E−11 | 6.59E−10 | CCR7, GRK3, ITK, CXCL10, CXCL12, CXCL3, CXCL2, CCL20, TIAM1, CCL2, PF4V1, CCL3, JAK3, PLCB4, JAK2, NFKBIA, CXCL8, CXCL1, STAT1, CXCL6, CXCL11, CXCL5, CCL7, CCL8, CCL5, HCK |
| Pathways in cancer | 36 | 2.09E−10 | 6.08E−09 | IL6, FGF11, KIT, NKX3–1, EGLN3, BIRC5, MITF, BIRC3, BDKRB1, WNT5A, IGF1, CXCL12, FGF7, ABL1, PTGS2, WNT5B, FGF5, EDNRB, RAD51, PLD1, BMP4, PLCB4, NFKBIA, CXCL8, NFKB2, AR, VEGFA, BMP2, FZD3, COL4A4, STAT1, SLC2A1, FGF2, LPAR1, TGFBR1, FOXO1 |
| NF-kappa B signalling pathway | 18 | 2.13E−10 | 6.08E−09 | IL1B, CD14, CXCL12, IL1R1, TNFAIP3, CXCL2, BCL2A1, PTGS2, ICAM1, NFKBIA, CXCL8, NFKB2, RELB, LBP, PLAU, BIRC3, TNFSF11, MAP3K14 |
| Haematopoietic cell lineage | 17 | 6.91E−10 | 1.78E−08 | IL6, IL1B, IL1A, IL1R1, ITGA1, CSF2, CD1D, IL11, CD38, ITGA4, IL7R, CD55, CSF3, KIT, CD14, IL1R2, IL11RA |